Match tier
Confirmed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
A
Asis Shrestha
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Assistant Professor
Faculty Researcher
COM | Internal Med Hem-Onc
1 pubs
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Asis Shrestha's research focuses on the prognostic impact of immune composition and clinical factors in patients with relapsed/refractory multiple myeloma undergoing bispecific antibody therapy. Their work investigates the influence of genomic and clinical high-risk features on treatment outcomes. Shrestha has also examined real-world infectious complications and IVIG utilization in this patient population.
Shrestha collaborates with researchers at the University of Arkansas for Medical Sciences, including Maurizio Zangari and Frits van Rhee, with whom they have co-authored multiple publications. Their recent publications are from 2026, indicating current activity in the field.
Metrics
- Publications: 1
Selected Publications
-
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
-
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Integrating Gene Expression With Recurrent Mutations Improves Age‐Stratified Risk Prediction in Acute Myeloid Leukemia (2026)
-
Abstract PS2-06-05: Comparing Cross-Toxicities and Efficacy of Everolimus and Alpelisib in Different Sequences in Metastatic Breast Cancer Patients (2026)
-
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)
-
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia (2025)
-
Producing high quality cranial SRS plans with 4Pi planning technique in a commercial clinical solution (2025)
-
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)
-
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)
-
The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia (2024)
-
Evans Syndrome: A Systematic Review (2024)
-
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP) (2024)
Collaboration Network
Top Collaborators
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
18 shared publications
In database
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
Showing 5 of 18 shared publications
Samer Al Hadidi
The University of Texas Southwestern Medical Center
15 shared publications
In database
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
Showing 5 of 15 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
14 shared publications
In database
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
Showing 5 of 14 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
13 shared publications
In database
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
Showing 5 of 13 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
12 shared publications
In database
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
Showing 5 of 12 shared publications
Hira Imad Cheema
University of Arkansas for Medical Sciences
8 shared publications
In database
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Showing 5 of 8 shared publications
Anup Kumar Trikannad
University of Arkansas for Medical Sciences
7 shared publications
In database
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Showing 5 of 7 shared publications
Niraj Neupane
Rochester General Hospital (US)
7 shared publications
- Racial Difference in Survival Outcomes of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. 2010 to 2020 NCDB Database Analysis
- Abstract PO3-06-03: Overall Survival and Disease Interval Among Breast Cancer Subtypes in Patients with Brain Metastasis
- Chalazion associated with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database.
- Multiple myeloma in the African American population: A 2010-2020 NCDB analysis.
- Efficacy and safety of GPRC5D-based monotherapies for relapsed/refractory multiple myeloma: A systematic review and meta-analysis.
Showing 5 of 7 shared publications
Binod Dhakal
Medical College of Wisconsin (US)
7 shared publications
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
- The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia
- Racial Difference in Survival Outcomes of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. 2010 to 2020 NCDB Database Analysis
Showing 5 of 7 shared publications
Mansi Shah
Cancer Institute (WIA) (IN)
7 shared publications
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
- The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia
- Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
Showing 5 of 7 shared publications
Aishee Bag
Rutgers, The State University of New Jersey (US)
6 shared publications
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
- The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia
- The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia
Showing 5 of 6 shared publications
Anita D’Souza
Medical College of Wisconsin (US)
6 shared publications
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
- The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia
- Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
Showing 5 of 6 shared publications
Rajshekhar Chakraborty
Columbia University Irving Medical Center (US)
6 shared publications
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
- Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
- The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia
Showing 5 of 6 shared publications
Nishi Shah
Albert Einstein College of Medicine (US)
6 shared publications
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
- The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia
- Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
Showing 5 of 6 shared publications
Meera Mohan
Medical College of Wisconsin (US)
6 shared publications
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
- Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
- The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia
- Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics
Stefan Longobardi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Clyde Baily
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Health Disparities and Outcomes
Farah Mazahvreh
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Retrospective Studies
Eric R. Siegel
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Susan Panozzo
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Health Disparities and Outcomes
Ahmad Mazin Safar
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Health Disparities and Outcomes